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The overall population incidence of venous thrombo-
embolism (VTE) is approximately 0.1% per year and
increases steeply with age.1 The commonest presen-
tation is lower limb deep vein thrombosis (DVT),
complicated in a proportion of patients by sympto-
matic acute pulmonary embolism (PE). The latter
remains the commonest single cause of potentially
preventable death in surgical and obstetric patients.
The commonest long-term complication of DVT is the
post-thrombotic syndrome (PTS), which develops in
up to 20% of cases, resulting in significant morbidity
and enormous health care and socio-economic costs.
Virchow’s Triad describes the risk factors for VTE;
namely, altered endothelium, blood flow and hyper-
coagulability (thrombophilia [TP]).2 TP may be
acquired or inherited, and may affect the clotting
and/or fibrinolytic cascades (Table 1, Fig. 1). The
classical ‘deficiency’ TP, such as protein C and S and
ATIII deficiency, can predispose to extensive and
atypical episodes of VTE in early life; especially if
more than one co-exists in the same patient along with
other environmental factors. However, as the majority
of patients affected by VTE do not apparently have a
‘deficiency’ TP, their contribution to the overall burden
of VTE remains difficult to define.3,4 Nevertheless, aing author. Rachel Sam, MA, MRCS, University
of Vascular Surgery, Research Institute, Lincoln
ingham Heartlands Hospital, Bordesley Green East,
B9 5SS, UK.
: rcsam@talk21.com
0539 + 06 $35.00/0 q 2005 Elsevier Ltd. All rights resersignificant proportion of DVT do develop in the
absence of apparently significant environmental risk
factors. This suggests that other, as yet incompletely
defined, TP may contribute to these so-called ‘idio-
pathic’ cases by raising patients above their thrombo-
tic threshold. Thus, in addition to the ‘deficiency’ TPs,
a growing group of ‘gain in function’ TPs is being
recognised. This review examines the evidence for the
role of coagulation factors VIII, IX, and XI in VTE, and
the implications of this new knowledge for clinical
practice.Factor VIIIThe relevant biology
Factor VIII (FVIII) is a vitamin-K dependent coagu-
lation factor, which is primarily synthesised in the
liver and circulates in plasma in a non-covalent
complex with von Willebrand factor (vWF). Stimu-
lation of coagulation cascade leads to the generation of
a small amount of thrombin, which along with factor
Xa, activates FVIII, resulting in its release from vWF. In
the absence of vWF the half-life of FVIII and its plasma
levels are greatly reduced.5 Once activated, FVIIIa acts
as a key co-factor in the FIXa-mediated conversion of
FX to FXa. Inactivation of FVIIIa results from
proteolytic cleavage by activated protein C (APC) or,
as it is intrinsically unstable, by spontaneous dis-
sociation. In haemophilia A, there is a congenitalEur J Vasc Endovasc Surg 30, 539–544 (2005)
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Table 1. Recognised thrombophilias and other risk factors for VTE
Inherited TP Acquired TP Environmental risk
factors
Protein C (PC)
deficiency
Antiphospholipid
syndrome
Age
Protein S deficiency Hyperhomocystei-
naemia (HHcy)
Pregnancy and
puerperium
Antithrombin
deficiency
Resistance to acti-
vated PC
Prolonged surgery
Factor V Leiden Dysfibrinogenaemia Malignancy
PT 20210 mutation Immobility
Hyperhomocystei-
naemia (HHcy)
Hormone therapy
R. C. Sam et al.540deficiency of FVIII resulting in a spontaneous haemor-
rhagic state. FVIII activity (FVIII:c) is measured by the
ability to correct the elevated activated partial
thromboplastin time (aPTT) of FVIII-deficient plasma.Fig. 1. An overview of the coagulation and fibrinolysis cas
degradation products).
Eur J Vasc Endovasc Surg Vol 30, 11 2005FVIII antigen (FVIII:Ag) is measured using a sandwich
enzyme-linked immunosorbent assay (ELISA). In
laboratories validated against international standards,
the normal range is 50–150 IU/dl where 1 ml of
pooled international standard plasma contains 1 unit
of FVIII.
ABO blood group genes are the main determinants
of vWF and thus as they are bound in plasma,
effectively determine normal FVIII levels. Group O
individuals have the lowest FVIII levels and AB the
highest levels, with the other group being intermedi-
ate.5,6 In the normal Caucasian population FVIII levels
are, therefore, skewed towards the upper end of
normal range. FVIII levels increase approximately
5% every 5–10 years independent of obesity, smoking
and hormonal status.7,8 Levels are also elevated incade (TF, tissue factor; TM, thrombomodulin; FDP, fibrin
Novel Venous Thrombophilias 541females and black ethnic groups.6 Transient rises are
seen after strenuous exercise and this may be
secondary to the effect of adrenaline.9 Acute inflam-
matory conditions will also result in a temporary
elevation in plasma level as part of the acute phase
reaction. Plasma FVIII levels are raised along with
vWF in pregnancy, surgery, chronic inflammation,
malignancy, liver disease, hyperthyroidism, intravas-
cular haemolysis, renal disease,5 hypertriglyceridae-
mia,10 hyperinsulinaemia,10 and in diabetes mellitus
(by up to 18%).8,10 This may be related to endothelial
cell damage or high levels of insulin in association
with insulin resistant.What is the nature and strength of the relationship between
FVIII and VTE?
The Leiden thrombophilia study (LETS) was the first
to report an association between elevated plasma FVIII
levels and VTE.11 Raised plasma FVIII levels (above
the 90th centile in control population) were found in
25% of unselected patients with their first objectively
confirmed venous VTE event compared with 11% in
healthy, age- and sex-matched controls. This signifi-
cant difference was independent of ABO status. This
association has been confirmed in two further
independent studies.12,13 On the basis of these data,
it is estimated that each 10 IU/dl increase in FVIII
plasma level is associated with a 17% increase in
thrombotic risk, even if level remain within the
‘normal range’. It is important to note that there is no
cut-off value above which a patient can be considered
to be FVIII ‘positive’.
High FVIII levels are a risk factor for recurrent VTE
although the strength of the association is less well
established.12,14,15 In the most recent prospective
study,15 patients with either ‘idiopathic’ VTE or
thrombotic events secondary to recognised environ-
mental events such as immobility and surgery were
followed up with objective testing for recurrent
episodes of VTE. In the ‘idiopathic’ group, there was
an independent, dose-dependent relationship
between FVIII levels and risk of recurrent disease,
with rates of recurrent VTE rising from 7% in those
with FVIII levels !25th centile (of this group), up to
23% of those with levels O90th centile. However, this
was not found to be the case in those patients in whom
there was an obvious precipitating event prior to the
index event.
High VIII levels probably act synergistically with
other TPs and risk factors such as the OCP. For
example, one study found a markedly increased VTE
risk in individuals with both high FVIII and factor VLeiden (FVL), compared with those with either TP in
isolation.16 In patients on the combined OCP elevated
FVIII levels was shown to increase the thrombotic risk
10-fold compared to those with lower FVIII levels.17What causes high FVIII levels?
High plasma FVIII levels can be regarded as both an
inherited and/or acquired TP for VTE. Although the
raised FVIII levels observed in patients with VTE was
originally considered to reflect the acute phase
response, subsequent work has shown that FVIII levels
remain elevated long after the acute phase response has
terminated and are independent of fibrinogen, eryth-
rocyte sedimentation rate (ESR) and C-reactive protein
(CRP).18,19 It has also been suggested that elevated
FVIII results from chronic endothelial cell (EC)
stimulation but levels do not correlate with other EC
markers such as soluble thrombomodulin (sTM), tissue
plasminogen activator (tPA), and plasminogen
activator inhibitor (PAI)-1.20 A strong relationship
exists between FVIII and vWF levels suggesting a
genetic basis for high FVIII levels.11,21,22 However, this
relationship is imperfect, suggesting the presence of
other genetic influences on FVIII levels related to
putative, but as yet unsubstantiated, polymorphisms
of the vWF FVIII binding domains, the vWF gene itself
and the aPC cleavage sites.12,23–25How do high FVIII levels result in VTE?
Elevated FVIII levels whether due to increased
synthesis, enhanced stability or reduced inactivation,
reduce the duration of the initiation phase of
coagulation and thus increase the generation of
thrombin.22,26,27 Thus, patients with VTE and elevated
FVIII have significantly higher levels of thrombin–
antithrombin (TAT) complexes (TAT) and prothrom-
bin (PF) fragments 1C2 levels compared with patients
with VTE and normal FVIII levels and normal healthy
controls.22 However, while there was a significant
relationship between FVIII and thrombin generation
when both groups of patients with VTE were analysed
together, this was not the case when those patients
with high FVIII were analysed alone. This suggests
that, above a certain level, FVIII may no longer be a
rate-limiting factor in thrombin generation. Alterna-
tively, another, as yet unidentified, factor may be
leading to high thrombin and FVIII levels in these
patients. Whatever the mechanisms, it is clear is that
high FVIII levels, even those that fall within the so-
called ‘normal range’, are associated with a marked
prothrombotic diathesis.Eur J Vasc Endovasc Surg Vol 30, 11 2005
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Factor IX is also vitamin K-dependent coagulation
factor which is synthesised in the liver. It is activated by
either the tissue factor (TF): FVIIa complex or by FXIa,
and in turn activates FX in the presence of FVIIIa and
platelets, or phospholipid (Fig. 1). Haemophilia B
(Christmas disease) is an X-linked recessive congenital
deficiency of FIX, which leads to a haemorrhagic state
that is clinically less severe than Haemophilia A.
Plasma levels are measured in a similar manner to
FVIII and the normal range is 50–150 IU/dl. Large
epidemiological studies have shown that FIX levels are
associated with a number of known risk factors for
VTE; namely, age,27,28 the oral contraceptive pill (OCP),
hormone replacement therapy (HRT), menopause,
body mass index, cholesterol, triglycerides, blood
pressure, smoking, and low socio-economic group-
ing.27–30What is the nature and strength of the relationship between
FIX and VTE?
FIX level was found to be an independent risk factor
for VTE in two recent case–control studies.28,31 In the
LETS study, patients with high plasma levels of FIX
(above the 90th centile of that found in control
population) had a two-fold increase in VTE risk. This
risk was higher in women and, as with FVIII,
significantly correlated with absolute levels.28 High
plasma FIX levels are also associated with recurrent
VTE in patients with unprovoked primary events,
with a similar dose-response effect. However, as with
FVIII, the size of this risk is less clear as the small
sample sizes inherent in these studies make multiple
adjustments for confounding variables difficult.32
High FIX levels also appear to interact with other
known TPs and risk factors for VTE.28,31 For example,
the presence of high FVIII and FIX levels results in an
eight-fold increase in VTE risk. Similar synergistic
effects have been found with aPC resistance and ATIII
deficiency, and the use of HRT.31What causes high FIX levels?
There is currently insufficient evidence to determine
whether high FIX levels have a genetic origin or
simply reflect environmental effects on FIX levels. It is
unlikely to be a result of an acute phase response as
factor IX is not an important reactant in inflammation,Eur J Vasc Endovasc Surg Vol 30, 11 2005and the VTE risk associated with high FIX is
unaffected by CRP levels.28How do high FIX levels result in VTE?
FIX levels are strongly associated with TAT and PF 1C
2.27 This appears to be due to TF-dependent and FX-
independent, thrombin generation. The fact that FIX
activation is dependent upon FVIII may explain their
synergistic effect on VTE risk.29Factor XIThe relevant biology
Factor XI circulates in complex with high molecular
weight kininogen (HMWK) and is then activated. The
most likely mechanisms of FXI activation in vivo is by
low levels thrombin on the surface of activated
platelets. FXI acts through a feedback effect on FIX
and FVIII, which results in high levels of thrombin, and
thus in turn leads to increased levels of thrombin
activated fibrinolysis inhibitor (TAFI) and thus inhi-
bition of fibrinolysis. Inherited factor XI deficiency, due
to genetic mutations on chromosome 4, results in a
moderate bleeding disorder most commonly seen in
Ashkenazi Jews and only sporadically in non-Jewish
populations. Tissues such as the oropharynx and the
urinary tract where there are high levels of local
fibrinolytic activity are primarily affected.33 There are
several circulating protease inhibitors of FXIa and
binding to platelets may partially protect it from
degradation.What is the nature and strength of the relationship between
FXI and VTE?
The association between high FXI levels and VTE has
only been determined very recently. In the LETS study,
patients with FXI levels O90th centile (of control
population) had a doubling of VTE risk that was
unaffected by sex, age, OCP and known genetic TPs.34
Further studies are awaited to confirm this relation-
ship with VTE, and determine the relationship with
recurrent VTE and other known TPs as well as the
origin of elevated FXI levels.Conclusion
It seems increasingly likely that the majority of
patients developing VTE have an inherited and/or
Novel Venous Thrombophilias 543acquired underlying abnormality of their coagulation
and/or fibrinolytic systems, in addition to the well-
recognised environmental risk factors such as surgery
and immobilisation. Specifically, there is growing
evidence of a causal association between FVIII, FIX
and, to a lesser extent FXI, levels and VTE, even when
levels are within the so-called ‘normal range’. This
additional risk has to be viewed in the light of the
overall clinical context and can be expressed in relative
or, more perhaps usefully when dealing with individ-
ual patients as opposed to populations, absolute
terms. The contribution that a particular TP makes to
the overall community burden of VTE (the attributable
risk) depends upon its thrombotic power (relative risk)
and the number of affected individuals (prevalence).
Although the ‘gain in function’ TPs, such as raised
factor levels and hyperhomocysteinaemia (HHcy),
may be ‘less powerful’ that some of the classical
‘deficiency’ TPs, their overall attributable risk is likely
to be far greater because they are much more
common.21
How should this new information impact upon
everyday clinical practice? In the majority of patients,
without a personal of family history of VTE, or another
known TP, routine full TP screen including measure-
ment of factor levels is probably not indicated prior to
environmental exposure of VTE risk; for example,
surgery. However, in patients who do exhibit one of
more of those pre-existing risk factors, knowledge of
the factor levels before and perhaps after surgery may
impact upon the nature and duration of VTE
prophylaxis. For example, a surgeon may wish to
continue low molecular weight heparin VTE prophy-
laxis post-discharge until factor levels return to normal
(or pre-operative) levels in a patient with a previous
VTE episode undergoing a femoro-distal bypass. In
addition in patients with multiple TP, it is vital that
this is included in the pre-operative consent process as
the greatly increased risk of VTE, even with prophy-
laxis may outweigh any benefit of the procedure.
Although this paper has specifically discussed VTE, it
is worth re-emphasising that some TP, including
raised factor levels, may also predispose to arterial
thrombosis of both native vessels and autogenous and
prosthetic conduits.35
In the absence of a major environmental VTE
stimulus such as surgery, it is generally agreed that
the risks of anticoagulation with warfarin probably
outweigh the benefits in patients with isolated raised
factor levels.32 However, in those with other known
TPs, anticoagulation might be justified on a case-by-
case basis, especially as safer anticoagulants such
ximelagatran36 enter the market. For this reason,
we would recommend that, in both surgical andnon-surgical patients deemed to be at high risk of VTE,
factor levels be included within the standard TP
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